Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial

Simple item page
dc.contributor.authorTan, Darrell HS
dc.contributor.authorRolón, María José
dc.contributor.authorFigueroa, Maria Ines
dc.contributor.authorSued, Omar
dc.contributor.authorGun, Ana
dc.contributor.authorKaul, Rupert
dc.contributor.authorRaboud, Janet M
dc.contributor.authorSzadkowski, Leah
dc.contributor.authorHull, Mark W
dc.contributor.authorWalmsley, Sharon L
dc.contributor.authorCahn, Pedro
dc.date.accessioned2024-05-23T23:49:45Z
dc.date.available2024-05-23T23:49:45Z
dc.date.issued2019-09-06
dc.descriptionFil: Rolon MJ. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.descriptionFil: Figueroa MI. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.descriptionFil: Sued O. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.descriptionFil: Gun A. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.descriptionFil: Cahn P. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.description.abstractBackground Inflammation has been associated with increased morbidity and mortality in HIV-positive patients. We compared inflammatory biomarkers with dual therapy using lopinavir/ritonavir plus lamivudine (LPV/r+3TC) versus triple therapy using LPV/r plus two nucleoside reverse transcriptase inhibitors (LPV/r+2NRTIs) in treatment-naïve HIV-positive adults. Methods This was a substudy among Argentinian participants in the randomized trial GARDEL. We measured hsCRP, IL-6, MCP-1, TNF, D-dimer and sCD14 from plasma collected at baseline, week 24 and week 48. Generalized estimating equations with an identity/logit link were used to model the average impact of dual versus triple therapy on each biomarker over time, controlling for baseline levels. Additional models estimated the average effect of virologic suppression on biomarker levels over time, adjusting for age, sex, and baseline CD4 count. Results Of 191 trial participants enrolled in Argentina, 172 had baseline and follow-up measurements and were included. Median (IQR) age was 35.5 (28.5, 45) years and CD4 cell count was 310 (219, 414) cells/mm3. Dual therapy was not associated with significantly different biomarker levels over 48 weeks relative to triple therapy. Virologic suppression was associated with statistically significant decreases in MCP-1, TNF and D-dimer levels and an unexpected increase in sCD14 levels. No change was observed in hsCRP or the proportion of participants with undetectable IL-6 levels. Conclusions In addition to having virologic non-inferiority, LPV/r+3TC dual therapy is generally associated with similar inflammatory biomarker levels over 48 weeks compared to LPV/r+2NRTIs triple therapy in treatment-naïve adults. Further study of dual treatment regimens is warranted.es_ES
dc.formatapplication/pdfes_ES
dc.identifier.doihttps://doi.org/10.1371/journal.pone.0221653
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/1397
dc.languageENGes_ES
dc.provenancePublishedes_ES
dc.relation.ispartofseriesPLoS ONE;2019 Sep 6;14(9):e0221653
dc.rightsopenAccesses_ES
dc.subjectBiomarkerses_ES
dc.subjectRandomized Controlled Triales_ES
dc.titleInflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized triales_ES
dc.typeArticuloes_ES

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
10.1371_journal.pone.0221653.pdf
Size:
506.01 KB
Format:
Adobe Portable Document Format
Description:
10.1371/journal.pone.0221653_eng
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download

Collections

Articulos científicos